The Types segment classifies the mRNA vaccine development services by the nature of the offering, shaping the market’s structural composition. Custom mRNA synthesis services, which include sequence design, codon optimization, and in‑vitro transcription, represent the foundational tier and capture the largest portion of service spend, as they are prerequisite for all downstream activities. Formulation and delivery services—encompassing lipid nanoparticle (LNP) engineering, microfluidic mixing, and stability optimization—form the second tier, reflecting the technical complexity of achieving efficient cellular uptake. Pre‑clinical testing services, such as animal model validation, immunogenicity assays, and toxicology studies, add a critical layer of value, particularly for high‑risk therapeutic areas like oncology. Finally, Regulatory and commercialization support—including IND preparation, CMC documentation, and market‑access consulting—constitutes a specialized niche that, while smaller in absolute spend, exerts outsized influence on time‑to‑market. Together, these type categories define the service portfolio that underpins the overall mRNA Vaccine Drugs Development Services market.